12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Graspa: Phase IIb started

Erytech said in March it began the open-label, European Phase IIb GRASPA-ML trial to compare 100 IU/kg Graspa in combination with low-dose cytarabine vs. cytarabine alone in about 123 patients ages 65-85 years. Graspa...

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >